Replies to post #126486 on Biotech Values

[hptaxis]

Do you have a link for the abstracts? Tia

[acgood]

Also from GSK/LGND

LB-3. Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated With Thrombocytopenia. N. Afdhal; G. Dusheiko; E. G. Giannini; P. Chen; K. Han; A. Moshin; M. Rodriguez-Torres; S. Rugina; E. Lawitz; M. L. Shiffman; G. Tayyab; F. Poordad; Y. Mostafa Kamel; A. Brainsky; J. Geib; S. Y. Vasey; R. Patwardhan; F. M. Campbell; D. Theodore

[pcrutch]

Other AASLD abstracts I missed for $VRTX's Incivek that could be of interest

"#LB-8. Telaprevir Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: 24-Week Treatment Interim Analysis."

"#LB-23. Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting."

"#248. Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-Based Regimens: Interim Analysis of the EXTEND Study."

"#31. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study."

"#32. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the Phase III REALIZE study."

"#35. Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)"

"#2117. Importance of newly described rare hepatitis C virus NS3 protease resistance mutations in patients treated with telaprevir or boceprevir."

"#2104. Long-term follow-up analysis of the hepatitis C virus NS3 protease in patients treated with telaprevir or boceprevir – a comparison between clonal and deep sequencing."

"#2088. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain From Wild Type Clone in Vivo."

#2105. Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage."

[DewDiligence]

VRTX commits to test 12w Incivek+VX-222+ifn+ribavirin in phase-3:

http://finance.yahoo.com/news/Interim-Data-from-Phase-2-bw-3000077287.html?x=0&.v=1

On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.

Here are the interim results from the phase-2 ZENITH study reported today at AASLD:



*50% (15/30) had undetectable hepatitis C virus at weeks 2 and 8 and were eligible to stop all treatment at week 12. Two people in the VX-222 (400 mg) treatment arm discontinued treatment before week 12 and did not achieve SVR12.

**38% (11/29) had undetectable hepatitis C virus at weeks 2 and 8 and were eligible to stop all treatment at week 12. Four people in the VX-222 (100 mg) treatment arm discontinued treatment before week 12 and two of them achieved SVR12.

+One person in the 12-week VX-222 (400 mg) treatment arm relapsed.

++Two people in the 12-week VX-222 (100 mg) treatment arm relapsed.